

**Remarks**

In view of the above amendments and the following remarks, reconsideration of the outstanding office action is respectfully requested.

Claim 1 has been amended, claims 3-5 have been cancelled without prejudice, and new claims 10-21 have been added. Descriptive support for new claims 10 and 11 appears in the first full paragraph on page 30 and the third full paragraph on page 35, respectively; descriptive support for new claims 12-14 appears in the first full paragraph on page 34; and descriptive support for new claims 15 and 16 appears in the first full paragraph on page 30. New claim 17 finds descriptive support in original claim 3 (i.e., claim written in independent form), and new claims 18-21 find descriptive support in original claims 4 and 6-8, respectively. Claims 1, 2, and 6-21 are pending.

The objection to the specification is overcome by the above amendments. Although applicants disagree with the assertion made by the U.S. Patent and Trademark (“PTO”), the present claim language is clearly supported by the first full paragraph on page 30, along with the disclosure of the nucleic acid sequence of SEQ ID NO: 147 and the corresponding amino acid sequence of SEQ ID NO: 148.

The objections to claims 1 and 5 are overcome by the above amendments and should be withdrawn.

The rejection of claims 1-9 under 35 U.S.C. §112 (first paragraph) as lacking written descriptive support is respectfully traversed.

The burden of establishing that an application lacks adequate written descriptive support falls on the PTO. *See In re Wertheim*, 541 F.2d 257, 263, 191 USPQ 90, 97 (CCPA 1976) (“[T]he PTO has the initial burden of presenting evidence or reasons why persons skilled in the art would not recognize in the disclosure a description of the invention defined by the claims.”). Hence, the PTO must demonstrate *why* the disclosure is insufficient.

The Federal Circuit has clearly espoused that *per se* conclusions of written description violations cannot be founded upon the basis of genus size alone. *See Enzo Biochem, Inc. v. Gen-Probe Inc.*, 296 F.3d 1316, 1326-27, 63 USPQ2d 1609, 1614-15 (Fed. Cir. 2002) (refusing to adopt position that three species as a matter of law cannot satisfy written description requirement for significantly larger genus). Thus, the PTO’s conclusion

cannot be based on genus size alone. But that is precisely what the PTO has done at pages 3-4 of the outstanding office action. Because the PTO's position is unsupported by law and unsupported by any facts other than genus size, applicants submit that the PTO's position cannot be sustained.

Applicants submit that the language recited in claims 1 and 9 is precisely the type of claim language that was acknowledged in *Univ. of California v. Eli Lilly*, 119 F.3d 1559, 43 USPQ2d 1398 (Fed. Cir. 1997) as being acceptable under the written description requirement. In *Eli Lilly*, the Federal Circuit addressed the validity of several claims of U.S. Patent No. 4,652,525 to Rutter et al. ("Rutter"), specifically those claims that recited the limitations 'vertebrate,' 'mammalian,' or 'human' cDNA for insulin. Rutter disclosed the nucleotide and amino acid sequences of a rat cDNA encoding insulin, but merely described a general procedure for obtaining the human cDNA encoding insulin. *Id.* at 1567, 43 USPQ2d at 1405. The Federal Circuit found that the description of the rat cDNA did not provide adequate descriptive support for the narrow subgenus of 'human' cDNA (no species disclosed), the larger subgenus of 'mammalian' cDNA (only the one rat species disclosed), and the larger genus of 'vertebrate' cDNA (only the one rat species disclosed). *Id.* at 1567-68, 43 USPQ2d at 1405. The Federal Circuit did acknowledge, however, the district court's statement that the specification provided adequate written descriptive support for the subgenus of 'rat' cDNA encoding insulin. *Id.* at 1566.

Thus, functional language should be acceptable when the genus as claimed is sufficiently limited in scope (i.e., from *Thermotoga* or *Thermotoga maritima*) and the specification describes one or more species within that genus. Claims 1 and 9 recite the same type of functional claim language that was identified as acceptable in *Eli Lilly* given the description of a single species by its nucleotide sequence. Thus, it should be evident that claims 1 and 9 (and claims dependent thereon) find written descriptive support in the present application.

In view of all of the foregoing, applicants submit that the rejection of claims 1-9 is improper and should be withdrawn.

The rejection of claims 1-9 under 35 U.S.C. §112 (first paragraph) for lack of enablement is respectfully traversed.

It is the position of the PTO that the specification does not provide sufficient guidance for making and using other delta prime subunit-encoding DNA molecules within the scope of the claims. Applicants respectfully disagree.

The PTO is respectfully reminded that all that is needed is objective enablement of what is claimed. *In re Wright*, 999 F.2d 1557, 1561, 27 USPQ2d 1510, 1513 (Fed. Cir. 1993). The present application provides the nucleotide sequence of *Thermotoga maritima holB* (e.g., SEQ ID NO: 147) and describes how one of ordinary skill can isolate homologs of the disclosed sequence (*see* page 41, line 9 to page 42, line 29), express the delta prime subunit encoded by such homologous *holB* sequences (*see* Example 20, expressing *A. aeolicus* delta prime subunit), and test the encoded delta prime subunit for clamp loader assembly competence (*see* Examples 24 and 25, testing *A. aeolicus* clamp loader assembly) and for clamp loader activity (*see* Examples 26 and 30, testing *A. aeolicus* clamp loader activity). Thus, one of ordinary skill in the art would have been fully able to make and use DNA molecules and their encoded proteins within the scope of the presently claimed invention.

In view of all of the foregoing, applicants submit that the rejection of claims 1-9 for lack of enablement is improper and should be withdrawn.

Because 1 is allowable for the reasons noted above, applicants further submit that new claims 10-16 also are allowable. Consistent with the PTO acknowledgments at pages 3-4 the outstanding office action, applicants further submit that the specification provides written descriptive support for and enables the claimed DNA molecules that encode the delta prime subunit having the amino acid sequence of SEQ ID NO: 148 (i.e., claims 17-21).

In view of all of the foregoing, applicant submits that this case is in condition for allowance and such allowance is earnestly solicited.

Respectfully submitted,

Date: August 23, 2006

/Edwin V. Merkel/

Edwin V. Merkel

Registration No. 40,087

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1128  
Facsimile: (585) 263-1600